Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.

Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger S, Herbst R, Schalper KA, Rimm DL.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33342-8. doi: 10.1016/j.jtho.2019.09.014. [Epub ahead of print]

PMID:
31605795
2.

Expression of circular RNA CDR1‑AS in colon cancer cells increases cell surface PD‑L1 protein levels.

Tanaka E, Miyakawa Y, Kishikawa T, Seimiya T, Iwata T, Funato K, Odawara N, Sekiba K, Yamagami M, Suzuki T, Ishibashi R, Otsuka M, Koike K.

Oncol Rep. 2019 Oct;42(4):1459-1466. doi: 10.3892/or.2019.7244. Epub 2019 Jul 19.

PMID:
31322270
3.

Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.

Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY.

Cancer Res Treat. 2019 Jun 25. doi: 10.4143/crt.2019.183. [Epub ahead of print]

4.

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.

Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, Yu J, Song Z, Zhou Q, Zhao F, Liu J, Zhang C, Dong H, Mutter RW, Lou Z.

Mol Cell. 2019 Jun 20;74(6):1215-1226.e4. doi: 10.1016/j.molcel.2019.04.005. Epub 2019 Apr 30.

PMID:
31053471
5.

An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade.

Zhao W, Zhao F, Yang K, Lu Y, Zhang Y, Wang W, Xie H, Deng K, Yang C, Rong Z, Hou Y, Li K.

J Cell Biochem. 2019 Aug;120(8):13330-13341. doi: 10.1002/jcb.28607. Epub 2019 Mar 27.

PMID:
30916827
6.

Bioinformatic analysis of the prognostic value of ZNF860 in recurrence-free survival and its potential regulative network in gastric cancer.

Pan HX, Bai HS, Guo Y, Cheng ZY.

Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):162-170. doi: 10.26355/eurrev_201901_16760.

PMID:
30767193
7.

Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma.

Zhu X, Qi G, Li C, Bei C, Tan C, Zhang Y, Shi W, Zeng W, Kong J, Fu Y, Tan S.

DNA Cell Biol. 2019 Feb;38(2):193-197. doi: 10.1089/dna.2018.4513. Epub 2018 Dec 18.

PMID:
30562063
8.

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.

Guan X, Zhang C, Zhao J, Sun G, Song Q, Jia W.

EBioMedicine. 2018 Sep;35:233-243. doi: 10.1016/j.ebiom.2018.08.012. Epub 2018 Aug 18.

9.

Systematic RNA-interference in primary human monocyte-derived macrophages: A high-throughput platform to study foam cell formation.

Domschke G, Linden F, Pawig L, Hafner A, Akhavanpoor M, Reymann J, Doesch AO, Erbel C, Weber C, Katus HA, Noels H, Erfle H, Gleissner CA, Runz H.

Sci Rep. 2018 Jul 12;8(1):10516. doi: 10.1038/s41598-018-28790-3.

10.

Association Between Polymorphisms in CMTM Family Genes and Hepatocellular Carcinoma in Guangxi of China.

Bei C, Tan C, Zhu X, Wang Z, Tan S.

DNA Cell Biol. 2018 Aug;37(8):691-696. doi: 10.1089/dna.2018.4274. Epub 2018 Jul 10.

PMID:
29990439
11.

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F.

Ann Transl Med. 2018 Feb;6(3):54. doi: 10.21037/atm.2017.11.26. No abstract available.

12.

Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

Imamovic D, Vranic S.

Ann Transl Med. 2017 Dec;5(23):467. doi: 10.21037/atm.2017.09.32. No abstract available.

13.

CMTM6 controls PD-L1.

Visan I.

Nat Immunol. 2017 Sep 19;18(10):1067. doi: 10.1038/ni.3844. No abstract available.

PMID:
28926544
14.

A recycling program that keeps PD-L1 out of the cancer cell's junkyard.

Griffin GK.

Sci Immunol. 2017 Sep 1;2(15). pii: eaao6869. doi: 10.1126/sciimmunol.aao6869. Epub 2017 Sep 1.

PMID:
28864496
15.

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA.

Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16.

16.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM.

Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16.

17.

Genome-wide analysis of positively selected genes in seasonal and non-seasonal breeding species.

Meng Y, Zhang W, Zhou J, Liu M, Chen J, Tian S, Zhuo M, Zhang Y, Zhong Y, Du H, Wang X.

PLoS One. 2015 May 22;10(5):e0126736. doi: 10.1371/journal.pone.0126736. eCollection 2015.

18.

Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model.

Yafune A, Kawai M, Itahashi M, Kimura M, Nakane F, Mitsumori K, Shibutani M.

Toxicol Lett. 2013 Oct 9;222(3):295-302. doi: 10.1016/j.toxlet.2013.08.006. Epub 2013 Aug 19.

PMID:
23968726
19.

A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth.

Li H, Li J, Su Y, Fan Y, Guo X, Li L, Su X, Rong R, Ying J, Mo X, Liu K, Zhang Z, Yang F, Jiang G, Wang J, Zhang Y, Ma D, Tao Q, Han W.

Oncogene. 2014 Jun 12;33(24):3109-18. doi: 10.1038/onc.2013.282. Epub 2013 Jul 29.

PMID:
23893243
20.

[Effect of testosterone on the expression of CMTM family of the male spermatogenesis suppression rats].

Li G, Li GY, Ji HJ, Zhao WJ, Chu SF, Chen NH.

Yao Xue Xue Bao. 2010 Aug;45(8):995-1000. Chinese.

PMID:
21351585

Supplemental Content

Loading ...
Support Center